Kris Houser
Psychiatry · Knoxville, TNNPI 1992798284
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 674 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 674 payments — averaging $21.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$2K
- Neurocrine Biosciences, Inc.$2K
- Alkermes, Inc.$987
- Lundbeck LLC$821
- plus $4K from 22 others
What the payments were for
- Food & beverage$14,296100%
- Education$470%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 148 | $2,620 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 72 | $2,127 |
| AbbVie(2 entities) | 94 | $1,993 |
| Neurocrine Biosciences, Inc. | 73 | $1,633 |
| Alkermes, Inc. | 33 | $987 |
| Lundbeck LLC | 59 | $821 |
| Axsome Therapeutics, Inc. | 35 | $758 |
| Johnson & Johnson | 19 | $606 |
| Teva Pharmaceuticals USA, Inc. | 28 | $511 |
| Vanda Pharmaceuticals Inc. | 22 | $465 |
| Idorsia Pharmaceuticals US Inc | 15 | $398 |
| Supernus Pharmaceuticals, Inc. | 12 | $254 |
| Sunovion Pharmaceuticals Inc. | 16 | $229 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $137 |
| Ironshore Pharmaceuticals Inc. | 3 | $127 |
| Bausch Health US, LLC | 6 | $115 |
| Almatica Pharma LLC | 6 | $110 |
| Neuronetics, Inc. | 4 | $102 |
| Adlon Therapeutics L.p. | 5 | $80 |
| E.r. Squibb & Sons, L.L.C. | 3 | $65 |
| Tris Pharma Inc | 3 | $55 |
| Arbor Pharmaceuticals, Inc. | 3 | $43 |
| Corium, LLC | 1 | $30 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Merck | 1 | $19 |
| Shire North American Group Inc | 1 | $13 |
| Indivior Inc. | 1 | $12 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$813
- VRAYLAR$617
- CAPLYTA$599
- ARISTADA$435
- REXULTI$373
- Auvelity$242
- SPRAVATO$205
- QUVIVIQ$122
- ABILIFY MAINTENA$122
- ABILIFY ASIMTUFII$122
- SUNOSI$122
- INGREZZA$121
- ARISTADA INITIO$109
How this compares
$14,343 in reported general payments places this provider in the 90th percentile of 503 psychiatry providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 27 | $222,340 |
| RexultiBrexpiprazole | 51 | $73,672 |
| CaplytaLumateperone Tosylate | 19 | $23,832 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 232 | $8,944 |
| Chlorpromazine Hcl | 28 | $6,372 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 24 | $4,070 |
| Doxepin Hcl | 119 | $3,691 |
| Asenapine Maleate | 16 | $2,821 |
| Vilazodone Hcl | 40 | $2,144 |
| Alprazolam | 586 | $2,006 |
| Hydroxyzine Hcl | 77 | $1,725 |
| Quetiapine Fumarate | 164 | $1,642 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 34 | $1,499 |
| Bupropion XlBupropion Hcl | 98 | $1,488 |
| Methylphenidate Hcl | 55 | $1,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,633 | $222,34027 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $2,620 | $73,67251 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,127 | $23,83219 claims |
| Almatica Pharma LLCSertraline Hcl | $110 | $39756 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 503 psychiatry providers in Tennessee.
Other psychiatry in Knoxville
- Karthi NamasivayamKnoxville$225K
- Lane CookKnoxville$53K
- Kelley WalkerKnoxville$17K
- Sharon BurnsideKnoxville$16K
- James KennedyKnoxville$15K
- Bryan WestKnoxville$15K
- Charles MayKnoxville$9K
- Julia WoodKnoxville$6K
- James RigellKnoxville$6K
- Rakesh AminNashville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.